Tag - PSH

Executive Moves

Sernova names Frank Shannon as VP clinical development, regulatory affairs

Frank Shannon Sernova (TSXV:SVA; OTC:SEOVF; FSE/XETRA:PSH) appointed 25-year pharmaceutical industry executive, Frank Shannon, as VP of clinical development and regulatory Affairs. Mr. Shannon most recently served...

June 30, 2021

Developments

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

Sernova (TSXV:SVA; OTC:SEOVF; FSE:PSH) reported additional positive preliminary safety and efficacy data for its Cell Pouch transplanted with insulin producing cells in patients with Type 1 diabetes. Data presented at...

January 15, 2021

Tag - PSH

Sernova names Frank Shannon as VP clinical development, regulatory affairs

Sernova’s Cell Pouch shows sustained clinical benefit in Type 1 diabetes

General

More